NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

MRK

Merck & Co Inc

Jul 11 • 04:00PM ET

83.36

Dollar change -0.66
Percentage change -0.79	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: PFE AZN NVS BMY JNJ AMGN ABBV GSK LLY SNY

| Held by: VTI VOO SCHD SPY IVV VTV XLV VIG VYM DGRO

Scroll to Statements

Index	DJIA, S&P 500	P/E	12.14	EPS (ttm)	6.87	Insider Own	0.07%	Shs Outstand	2.52B	Perf Week	3.00%
Market Cap	209.32B	Forward P/E	8.55	EPS next Y	9.75	Insider Trans	-0.19%	Shs Float	2.51B	Perf Month	2.47%
Enterprise Value	234.90B	PEG	1.03	EPS next Q	2.03	Inst Own	80.32%	Short Float	1.40%	Perf Quarter	1.77%
Income	17.43B	P/S	3.28	EPS this Y	15.80%	Inst Trans	0.81%	Short Ratio	2.18	Perf Half Y	-17.48%
Sales	63.78B	P/B	4.34	EPS next Y	10.05%	ROA	15.78%	Short Interest	35.09M	Perf YTD	-16.20%
Book/sh	19.21	P/C	22.43	EPS next 5Y	11.83%	ROE	39.31%	52W High	129.93 -35.84%	Perf Year	-33.86%
Cash/sh	3.72	P/FCF	12.28	EPS past 3/5Y	9.42% 12.04%	ROIC	21.31%	52W Low	73.31 13.71%	Perf 3Y	-10.49%
Dividend Est.	3.12 (3.75%)	EV/EBITDA	8.80	Sales past 3/5Y	9.36% 6.55%	Gross Margin	74.68%	Volatility	2.38% 2.35%	Perf 5Y	9.86%
Dividend TTM	3.20 (3.84%)	EV/Sales	3.68	EPS Y/Y TTM	654.93%	Oper. Margin	34.71%	ATR (14)	1.99	Perf 10Y	51.59%
Dividend Ex-Date	Jun 16, 2025	Quick Ratio	1.16	Sales Y/Y TTM	4.40%	Profit Margin	27.33%	RSI (14)	60.87	Recom	1.84
Dividend Gr. 3/5Y	5.73% 6.66%	Current Ratio	1.41	EPS Q/Q	7.20%	SMA20	3.11%	Beta	0.40	Target Price	103.05
Payout	46.32%	Debt/Eq	0.72	Sales Q/Q	-1.20%	SMA50	5.03%	Rel Volume	0.57	Prev Close	84.02
Employees	75000	LT Debt/Eq	0.69	Earnings	Jul 29 BMO	SMA200	-9.75%	Avg Volume	16.13M	Price	83.36
IPO	Jun 15, 1946	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.09% 1.24%	Trades		Volume	9,717,398	Change	-0.79%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-25	Downgrade	Citigroup	Buy → Neutral	$84
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$85
Feb-18-25	Downgrade	Deutsche Bank	Buy → Hold	$128 → $105
Feb-10-25	Downgrade	TD Cowen	Buy → Hold	$121 → $100
Jan-08-25	Downgrade	Truist	Buy → Hold	$110
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$136 → $105
Dec-10-24	Resumed	BofA Securities	Buy	$121
Dec-04-24	Upgrade	HSBC Securities	Hold → Buy	$130
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-11-24	Downgrade	Daiwa Securities	Buy → Neutral
Oct-17-24	Initiated	Bernstein	Mkt Perform	$115
Mar-11-24	Downgrade	Societe Generale	Hold → Sell	$104
Jan-04-24	Upgrade	TD Cowen	Market Perform → Outperform	$125 → $135
Nov-09-23	Initiated	Deutsche Bank	Buy	$115
Oct-27-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$132
Oct-20-23	Upgrade	UBS	Neutral → Buy	$117 → $122
Jul-14-23	Initiated	HSBC Securities	Hold	$123
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130
Mar-28-23	Downgrade	Societe Generale	Buy → Hold
Mar-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$120 → $115

Show Previous Ratings

Today 01:30AM	Biotech Stocks Are Ready to Rebound. 3 to Watch Now. (Barrons.com)
Jul-13-25 05:00PM	China Biotechs Stunning Advance Is Changing the Worlds Drug Pipeline (Bloomberg)
07:01AM	Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs. (The Wall Street Journal)
05:30AM	Will Trumps 200% tariff threat on pharma really materialize? (Investing.com)
Jul-12-25 02:34PM	Merck & Co., Inc. (MRK)'s CEO Thinks He's Got $50 Billion Of New Drugs, Says Jim Cramer (Insider Monkey)
09:36AM	Loading…
09:36AM	FDA willing to trade faster drug reviews for lower prices, Bloomberg reports (TipRanks)
12:15AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Jul-11-25 04:56PM	Big pharma's multiple looming patent cliffs: What to know (Yahoo Finance Video)
04:56PM	Top Analyst Reports for Microsoft, Alibaba & Merck (Zacks)
12:12PM	FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill (Zacks)
10:41AM	MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success (Zacks)
08:19AM	Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock? (Zacks)
07:15AM	With Verona deal, Merck wagers on strength of lung drugs patents (BioPharma Dive)
05:36AM	2 Top Stocks Down 16% and 17% This Year to Buy and Hold (Motley Fool)
Jul-10-25 04:45PM	FDA Approves BRAVECTO QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health (Business Wire)
02:59PM	Loading…
02:59PM	Pod Digital Media Celebrates Seven Years of Connecting Brands Authentically to Growth Audiences (Business Wire)
01:47PM	Veteran analyst sends bold message on Palantir stock target (TheStreet)
11:40AM	Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration (Insider Monkey)
09:47AM	Alcohol Related Liver Disease Market Forecast, 2025-2035 \| Personalized Medicine Transforming ARLD Treatment Landscape (GlobeNewswire)
06:59AM	Trump Says Powell's Fed Job Is Easy. Why Nvidia, Bitcoin, Market Rally Say Otherwise and 5 Other Things to Know Today. (Barrons.com)
06:45AM	U.S. FDA Accepts New Drug Application for Mercks Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection (Business Wire)
04:57AM	Merck agrees to acquire Verona Pharma for $10bn (Pharmaceutical Technology)
04:04AM	Zacks Investment Ideas feature highlights: QQQ, IWM, SBET, CRCL, COIN, AES, MRK and VRNA (Zacks)
Jul-09-25 06:35PM	Podcast: Trump Sends More Tariff Letters; Nasdaq Climbs to Record (The Wall Street Journal)
05:50PM	Merck (MRK) Rises Higher Than Market: Key Facts (Zacks)
05:03PM	Merck will have 'a lot more work to do' after Verona deal (Yahoo Finance Video)
04:16PM	How major US stock indexes fared Wednesday, 7/9/2025 (Associated Press Finance)
04:13PM	Stocks to Watch Wednesday: Freeport-McMoRan, AES, Merck, Fair Isaac (The Wall Street Journal)
04:09PM	Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma (Investor's Business Daily)
02:47PM	Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps (Benzinga)
01:45PM	Loading…
01:45PM	Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade (Reuters)
01:19PM	Trump's newest tariffs, Merck & Verona, X CEO resigns (Yahoo Finance Video)
01:15PM	Merck's stock among S&P 500's leaders after $10 billion Verona Pharma deal (MarketWatch)
12:55PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
12:29PM	Health Care Roundup: Market Talk (The Wall Street Journal)
12:07PM	Merck to Buy Verona Pharma for Around $10 Billion (Bloomberg)
12:05PM	Top Stock Movers Now: Nvidia, AES, WPP, and More (Investopedia)
11:17AM	What You Need To Know Ahead of Merck's Earnings Release (Barchart)
10:36AM	Merck to Buy Verona Pharma in $10 Billion Deal (The Wall Street Journal)
10:11AM	Merck Is Buying Lung-Disease Biotech in $10 Billion Deal (Barrons.com)
10:04AM	Verona Phama Stock Soars to All-Time High as Merck Buys Firm for $10B (Investopedia)
09:46AM	Pharma latest: Merck to acquire Verona, Trump pharma tariffs (Yahoo Finance Video)
09:34AM	Tariff Turbulence and Overbought Tech Mark Post-Holiday Trading (Zacks)
09:24AM	Merck Faces Multiple Challenges: Will It Steer Through Successfully? (Zacks)
09:20AM	Will Recent Label Expansions of Opdivo Help BMY Gain Momentum? (Zacks)
09:19AM	Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck (Zacks)
09:19AM	GSK's Specialty Medicines Unit on a Strong Footing: Here's Why (Zacks)
09:10AM	Stock Market Today: Dow Jones Index Rises Ahead Of Fed Minutes; Microsoft Climbs On Upgrade (Live Coverage) (Investor's Business Daily)
09:09AM	UBS Affirms Merck & Co's (MRK) 'Buy' Rating on HPV Vaccine Prospects (Insider Monkey)
08:40AM	Trump Unleashes Tariff Tsunami: Copper at 50%, Pharma Faces 200% -- Markets Rattle (GuruFocus.com)
07:48AM	Trump's tariffs target copper, pharma, Merck to acquire Verona: 3 Things (Yahoo Finance Video)
07:48AM	Merck dives into COPD treatments with $10 billion purchase of Verona Pharma (MarketWatch)
07:42AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:29AM	Trump's Drug Tariffs: Where Does the U.S. Import Pharmaceuticals From? (The Wall Street Journal)
07:14AM	Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck. (Barrons.com)
07:06AM	Merck spends $10 billion for Verona, gaining access to its COPD medication (Associated Press Finance)
06:39AM	Merck to acquire Verona Pharma for $10 billion (Reuters)
06:30AM	Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade (Business Wire)
04:43AM	Biomarkers Market Research Report 2025-2030 \| Assay Kit Demand Surges as Advancements in Omics Technologies Elevate Biomarker Discovery and Diagnostic Precision (GlobeNewswire)
01:09AM	Merck shells out $10 billion for London-based lung therapy firm Verona (Reuters)
Jul-08-25 11:34PM	Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK) (StockStory)
04:20PM	Centivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity Portfolio (PR Newswire)
02:18PM	Trump Says Hell Set 50% Copper Tariff, Wait Year on Drug Levies (Bloomberg)
01:31PM	Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months (MarketWatch)
10:43AM	AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth? (Zacks)
10:25AM	Equine Healthcare Market Research and Forecast Report 2025-2034 \| Top Players Drive Innovations, Strategic Collaborations and Product Expansion on the Rise (GlobeNewswire)
09:51AM	Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock? (Zacks)
09:00AM	Impactivize: Shareholders of 30 Companies Worth $13 Trillion Vote Overwhelmingly to Defeat Anti-DEI Proposals (PR Newswire)
08:00AM	Certara Announces Expansion of Clinical Technology Collaboration with Merck (GlobeNewswire)
06:45AM	Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025 (Business Wire)
06:03AM	Analysis: 'Trump Effect' website takes credit for US investment made under Biden (Reuters)
Jul-07-25 09:22AM	Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock? (Zacks)
08:52AM	SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca (Zacks)
08:30AM	Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs (PR Newswire)
07:30AM	Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? (Motley Fool)
07:17AM	mRNA Cancer Vaccines Clinical Trials & Future Market Outlook 2025: Personalized mRNA Cancer Vaccines Revolutionize Oncology with Neoantigen-Driven Immunotherapy (GlobeNewswire)
Jul-06-25 03:35AM	FDA Grants Priority Review for Merck & Co's (MRK) WINREVAIR (Insider Monkey)
03:35AM	Merck & Co (MRK) Announces the Approval of ENFLONSIA (Insider Monkey)
Jul-04-25 09:53AM	Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance? (Zacks)
04:00AM	Sodium Perborate Market worth $184.0 million in 2030, at 3.7%, says MarketsandMarkets (GlobeNewswire)
03:22AM	TD Cowen Maintains Hold Rating on Merck After Enflonsia Vaccine Update (Insider Monkey)
Jul-03-25 05:50PM	Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
09:26AM	Will The Decline in Legacy Drugs Pull Down BMY's Top Line? (Zacks)
08:30AM	MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE (Zacks)
08:20AM	Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth (Zacks)
02:47AM	Merck & Co. (MRK) Announces that US FDA Approves ENFLONSIA For Preventing RSV Lower Respiratory Tract Disease (Insider Monkey)
Jul-02-25 05:30PM	Merck's Drug Slashes PAH Risk by 76%--FDA Fast-Tracks Game-Changer (GuruFocus.com)
07:03AM	Merck concludes SpringWorks acquisition for $3.4bn (Pharmaceutical Technology)
06:45AM	FDA Grants Priority Review for WINREVAIR (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial (Business Wire)
04:00AM	Can China sustain a surge in oncology drug innovation? (Pharma Voice)
Jul-01-25 06:09PM	Trading Rotation Kicks Off 2nd Half of 2025 (Zacks)
12:10PM	Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:35AM	Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth (Zacks)
06:45AM	Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29 (Business Wire)
Jun-30-25 09:50AM	BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock? (Zacks)
07:55AM	Gilead extends gains after Supreme Court upheld an Obamacare provision (Investing.com)
Jun-28-25 10:09AM	3 Absurdly Cheap Stocks Ready for a Breakout (Motley Fool)
02:15AM	Should You Count on MRK for Steady Passive Income? (Insider Monkey)
Jun-27-25 09:35AM	Cancer Vaccine (Preventative, Therapeutic) Market Research 2025 with Analyst Recommendations-Leveraging AI and Bioinformatics for Precision Development / Pursue Fast-Track and Orphan Drug Designations (GlobeNewswire)
Jun-26-25 05:50PM	Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smart Dalton E. III	SVP Fin. - Global Controller	May 03 '25	Option Exercise	83.18	2,050	170,519	10,127	May 05 04:23 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 30 '25	Option Exercise	84.71	464	39,305	8,242	May 02 04:18 PM
Smart Dalton E. III	SVP Fin. - Global Controller	May 02 '25	Option Exercise	83.26	381	31,722	8,464	May 02 04:18 PM
Romanelli Joseph	President, Human Health Int?l	May 02 '25	Option Exercise	83.26	2,262	188,334	24,061	May 02 04:14 PM
Romanelli Joseph	President, Human Health Int?l	Apr 30 '25	Option Exercise	84.71	2,063	174,757	22,816	May 02 04:14 PM
Larson Betty D	EVP, Chief HR Officer	Apr 30 '25	Option Exercise	84.71	11,350	961,458	11,350	May 02 04:12 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Option Exercise	58.08	5,000	290,400	12,040	Apr 29 04:04 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Sale	82.76	4,262	352,723	7,778	Apr 29 04:04 PM
DALTON SMART	Officer	Apr 25 '25	Proposed Sale	82.76	4,262	352,723		Apr 25 04:05 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 19 '25	Sale	84.09	8,500	714,745	30,705	Feb 20 04:01 PM
JOHANNES JACOBUS OOSTHUIZEN	Officer	Feb 19 '25	Proposed Sale	84.09	8,500	714,745		Feb 19 05:09 PM
DAVID WILLIAMS	Officer	Feb 13 '25	Proposed Sale	85.34	6,000	512,057		Feb 13 04:10 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 13 '25	Sale	85.34	6,000	512,057	24,123	Feb 13 04:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 08 '25	Option Exercise	87.28	13,002	1,134,815	45,609	Feb 11 02:59 PM
THULIN INGE G	Director	Feb 06 '25	Buy	88.25	2,833	250,000	2,933	Feb 07 04:09 PM
Downing Cristal N	Chief Comm. & Public Afrs Ofcr	Feb 06 '25	Sale	88.76	2,361	209,551	7,085	Feb 07 04:07 PM
BAKER DOUGLAS M JR	Director	Feb 05 '25	Buy	88.50	15,000	1,327,500	16,000	Feb 07 04:04 PM
CRISTAL DOWNING	Officer	Feb 06 '25	Proposed Sale	88.76	2,361	209,551		Feb 06 04:43 PM
Guindo Chirfi	Chief Marketing Officer	Aug 05 '24	Option Exercise	115.20	36,901	4,250,995	57,782	Aug 06 12:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK

Merck & Co Inc

Upgrade your FINVIZ experience